IPR decision (February 7, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Status
|
|
IPR2016-01370
|
July 20, 2016
|
Feb 8, 2017
|
Koios Pharmaceuticals LLC
|
US 8,664,231
|
Final Written Decision
(claims 1–22 are patentable)
|
On US’231 patent, Antares & Frontier Therapeutic previously filed IPRs (IPR2014-01091 & IPR2016-00649) which were terminated by PTAB.
US 8,664,231 (Medac; 06/01/2029) – OB listed
1. A method for the treatment of inflammatory autoimmune diseases in a patient in need thereof, comprising subcutaneously administering to said patient a medicament comprising methotrexate in a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml.
Leave a Reply